- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06370793
Ningbo Severe Mental Disorders Cohort (NEED)
Ningbo Severe Mental Disorders Cohort, a Longitudinal Population-based Ambispective Cohort Study
In recent years, the prevalence of severe mental disorders in China has continued to grow, and the burden of disease in society has continued to rise. In order to improve the prognosis of patients with severe mental disorders and reduce the risk of disease relapse or readmission, researchers established a cohort based on the Ningbo Mental Health Information System in Ningbo, a sub-provincial city in the southern wing of the Yangtze River Delta of China, with a resident population of more than 9 million, and linked it to the residents' health records, and through the data linkage obtained data on patients in the full cycle of pre-diagnosis, diagnosis, follow-up, disease changes and death, realising full-cycle management of patients with severe mental disorders.
Currently, NEED has accumulated data on more than 50,000 patients with severe mental disorders and obtained multi-dimensional longitudinal information through long-term follow-up and data linkage. All diseases follow the World Health Organization International Classification of Diseases 10th Edition (ICD-10) for clinical coding, and available data include baseline demographics, past history, family history, social functioning deficit screening scale scores, risk assessment, and so on and longitudinal health information from electronic health records (EHR), providing a solid data base for future real-world studies.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Ningbo, Zhejiang, China, 315000
- Ningbo Mental Health Information System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of schizophrenia (F20)
- Clinical diagnosis of schizo-affective disorder (F25)
- Clinical diagnosis of paranoid psychoses (F22)
- Clinical diagnosis of bipolar disorder (F30-F31)
- Clinical diagnosis of epileptic psychosis (F06.8)
- Clinical diagnosis of mental retardation (F70-F79)
Exclusion Criteria:
- None.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with severe mental disorders
|
Patients with severe mental disorders identified based on exposures of interest to the study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk of circulatory system diseases
Time Frame: At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Primary hypertension (I10), Cerebral infarction (I63), Transient cerebral ischaemic attacks and related syndromes (G45), Intracerebral haemorrhage (I61), Subarachnoid haemorrhage (I60), Hemorrhagic stroke (I60-I61), Stroke (I60-I64, I69), Pulmonary embolism (I26), Aortic aneurysm and dissection (I71), Cardiovascular disease (I20-I25), Atrial fibrillation (I48), Cardiomyopathy (I42), Peripheral vascular diseases (I73), Myocardial infarction (I21-I22), Heart failure (I50). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Risk of endocrine system diseases
Time Frame: At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Diabetes mellitus (E10-E14), Thyroid disorder (E00-E05, E61-E69, E07), Gout (E79, M10). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Risk of pulmonary system and allergy diseases
Time Frame: At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Chronic pulmonary disease (J40-J47), Allergy (J30.1-J30.4, L23, L50.0, T78.0, T78.2, T78.4). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Risk of gastrointestinal system diseases
Time Frame: At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Ulcer/chronic gastritis (K22.1, K25-K28, K29.3-K29.5), Chronic liver disease (B16-B19, K70, K74, K76.6, I85), Inflammatory bowel disease (K50-K51), Diverticular disease of intestine (K57). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Risk of musculoskeletal system diseases
Time Frame: At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records :Connective tissue disorders (M05-M06, M08-M09, M30-M36, D86), Osteoporosis (M80-M82). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Risk of urogenital system diseases
Time Frame: At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : Chronic kidney disease (N03, N11, N18-N19), Prostate disorders (N40). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Risk of hematological system diseases
Time Frame: At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records : HIV/AIDS (B20-B24), Anemias (D50-D53, D55-D59, D60-D61, D63-D64). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Risk of cancers
Time Frame: At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Diagnosed with cancer (C00-C43, C45-C97) in electronic health records.
Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders.
|
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Risk of neurological system diseases
Time Frame: At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
At least one of the following diagnoses in the electronic health records :Vision problem (H40, H25, H54), Hearing problem (H90-H91, H93.1), Migraine (G43), Epilepsy (G40-G41), Parkinson's disease (G20-G22), Multiple sclerosis (G35), Neuropathies (G50-G64). Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
At least 1 year after being diagnosed with severe mental disorders during the study period (2019-2023)
|
Risk of suicide
Time Frame: Recorded during the study period (2019-2023)
|
At least one of the following records in the Ningbo Mental Health Information System: attempted suicide, suicide, death by suicide. Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
Recorded during the study period (2019-2023)
|
Risk of violence
Time Frame: Recorded during the study period (2019-2023)
|
At least one of the following records in the Ningbo Mental Health Information System: causing trouble, causing an accident, committing an offence, injuring another person. Calculation of Hazard ratios(HRs) with 95% confidence intervals, comparing the risk of illness in persons with severe mental disorders with those without severe mental disorders. |
Recorded during the study period (2019-2023)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Mood Disorders
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Schizophrenia Spectrum and Other Psychotic Disorders
- Bipolar and Related Disorders
- Neurodevelopmental Disorders
- Schizophrenia
- Psychotic Disorders
- Mental Disorders
- Bipolar Disorder
- Paranoid Disorders
- Intellectual Disability
- Affective Disorders, Psychotic
Other Study ID Numbers
- NBU-2024-011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Patient with severe mental disorder without intervention
-
Groupe Hospitalier Paris Saint JosephWithdrawnChronic Inflammatory Demyelinating Polyradiculoneuropathy
-
Columbia UniversityNot yet recruitingGlaucoma | Diabetic Retinopathy | Cataract | Vision Impairment and BlindnessUnited States
-
Riphah International UniversityCompleted
-
Massachusetts General HospitalNational Institute on Minority Health and Health Disparities (NIMHD)CompletedMental DisordersUnited States, Puerto Rico
-
Poitiers University HospitalCompleted
-
University of HoustonRecruitingMental DisorderUnited States
-
Uppsala UniversityVästmanland County Council, SwedenTerminatedDepression | Depressive SymptomsSweden
-
Bursa Yüksek İhtisas Education and Research HospitalCompleted
-
University of California, San DiegoRecruitingObesity | Diabetes | Schizophrenia | Serious Mental Illness | Lifestyle Risk ReductionUnited States